The pharmaceutical giants reached a settlement agreement that terminated the intellectual property dispute filed in 2023. AstraZeneca had sued Sun Pharmaceutical Industries Limited and its U.S. subsidiary Sun Pharmaceutical Industries Inc. in Delaware federal court, though the specific patents and products at issue were not detailed in the dismissal order.
Under the terms of the stipulated dismissal filed pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), both sides agreed to bear their own costs, disbursements and attorneys' fees. Judge Andrews noted in his order that the dismissal covers all claims and defenses between the parties.
The case was filed in the District of Delaware in 2023, a popular venue for patent litigation due to its specialized expertise in intellectual property matters. The dismissal without prejudice means AstraZeneca could potentially refile similar claims in the future, though such action appears unlikely given the apparent settlement.
The resolution follows a pattern of pharmaceutical companies increasingly settling patent disputes out of court to avoid lengthy and costly litigation. Both AstraZeneca and Sun Pharma are major players in the generic drug market, where patent battles over brand-name medications are common as generic manufacturers seek to enter the market.